Unnatural Products
Also known as UNP, Unnatural Products, Inc.
Designs macrocyclic peptides, ring-shaped molecules meant to reach hard targets and be taken as pills, with a platform that pairs parallel synthesis and screening with machine learning; partners include argenx, Novartis, Merck and BridgeBio.
argenx agreed on 9 November 2026 to buy the shares it did not already hold, for $550 million upfront and up to $595 million in milestones; closing is expected by the end of 2026, and the team stays in Santa Cruz as argenx's peptide discovery site.
Money and evidence
No research by this company is on the record yet.
Rounds and research, on one timeline
- 2026-03-16Series BRound
$45M
For: building a wholly owned pipeline and taking at least one programme into the clinic, as CEO Cameron Pye put it
Toward the clinic
Read as Endpoints News' interview with CEO Cameron Pye, reposted by participant Droia Ventures; UNP's own release on GlobeNewswire refused automated readers.
Lead · The Venture CollectiveDroia Ventures ✓Existing investor · argenxExisting investor · Merck Global Health Innovation FundExisting investor · ARTIS VenturesExisting investor · First Spark Ventures
The investor's own page says · Droia Ventures: Files Endpoints News' Series B report under its Unnatural Products portfolio posts
- 2023-12-20Series ARound
$32M
For: advancing its platform and widening its focus beyond oncology
Models and platform
Co-lead · Merck Global Health Innovation FundCo-lead · ARTIS VenturesFirst Spark VenturesThe Venture CollectiveHumain VenturesLongeVCNot Boring Capital
- 2019-09-17SeedRound
$6 million ("more than $6 million" in Santa Cruz Tech Beat's copy)
For: growing the team, developing the platform and advancing its oncology programmes
HiringModels and platform
Lead · ARTIS VenturesAbstract VenturesAsset Management VenturesBetter VenturesBlue Bear VenturesRising Tide Fund
Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.
On the investors' own sites
Investors that name this company on their own site, in a portfolio or their own announcement. A ✓ in a round marks the same investor.
- Droia VenturesFiles Endpoints News' Series B report under its Unnatural Products portfolio postsdroiaventures.com ↗
Its investors also backed
Other companies on this page whose rounds name the same investor.
- Merck Global Health Innovation FundBigHat Biosciences
- First Spark VenturesRadical Numerics